Results 151 to 160 of about 63,205 (262)
Current Advances of Molecular Biomarkers and Liquid Biopsies Techniques in Ovarian Cancer
ABSTRACT Ovarian cancer (OC) remains a lethal gynecological malignancy with challenges in early diagnosis, treatment monitoring, and overcoming drug resistance. Liquid biopsy, a noninvasive approach analyzing tumor‐derived components in bodily fluids, has emerged as a promising tool in OC management.
Jingxia Zhang +5 more
wiley +1 more source
Identification and Characterization of Novel Inhibitors of Human Poly(ADP-Ribose) Polymerase-1. [PDF]
Morgan I +6 more
europepmc +1 more source
ABSTRACT Aims To evaluate the proportion of expressed programmed cell death ligands‐1 (PD‐L1) in epithelial ovarian carcinoma patients, and the association with the clinicopathological, surgical outcomes, and oncologic outcomes. To compare PD‐L1 protein expression with messenger ribonucleic acid (mRNA) expression. Methods The patients who had pathology
Achjima Tankul +8 more
wiley +1 more source
Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer. [PDF]
Uekusa R +9 more
europepmc +1 more source
ABSTRACT Background Small mothers against decapentaplegic homologue 4 (SMAD4) plays an important role in transforming growth factor (TGF)‐β signaling and is associated with various cancers. However, little is known about SMAD4 expression in oral squamous cell carcinoma (OSCC).
Junki Sakata +15 more
wiley +1 more source
Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer
Chia-Hao Liu, Yi Chang
doaj +1 more source
Poly (ADP-Ribose) Polymerase 1 and 2 in B-Cell Lymphoma: Pathogenic Roles and Therapeutic Implications. [PDF]
Molina-Alvarez A +3 more
europepmc +1 more source
ABSTRACT Background Ovarian carcinosarcoma (OCS) is a rare, aggressive tumor composed of both carcinomatous and sarcomatous components, typically associated with poor prognosis. Due to its rarity, the molecular characteristics, immune microenvironment, and optimal treatment of OCS remain unclear.
Tomomi Sakamaki +14 more
wiley +1 more source
Recurrent patterns and prognostic factors based on CA-125 and RECIST progression in ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors. [PDF]
Zhang B +7 more
europepmc +1 more source

